Early Warning News Release of Invidx Corp.
December 15, 2014
Invidx Corp. ("Invidx"), a company controlled by James Samsoondar, the Chief Science Officer and director of the Company, announces that it has acquired ownership and control of 5,474,452 common shares of ChroMedX Corp. (the "Company" or "ChroMedX") through the exercise of an ultrafiltration option by ChroMedX. Prior to this acquisition, Invidx held 15,000,100 common shares of ChroMedX.
There are currently approximately 42,874,644 common shares of ChroMedX issued and outstanding. Invidx has ownership over an aggregate of 20,474,552 common shares of the Company on an undiluted basis, representing 47.75% of the issued and outstanding common shares of the Company. Invidx does not own any convertible securities of the Company.
Invidx acquired the securities on an exercise of an ultrafiltration option and may make additional investment in or dispositions of securities of the Company, depending on price, availability and general market conditions.
A copy of the Early Warning Report filed under applicable Canadian provincial securities legislation in connection with Invidx's shareholdings in ChroMedX may be found at www.sedar.com under ChroMedX's profile.
For more information, please contact:
Dr. James Samsoondar
T: (905) 471-3930